Antonis Giakountis, PhD, University of Thessaly, Greece
Molecular Medicine is calling for submissions to our Collection on Weaponizing RNA biology for combating complex diseases: From bulk transcriptome analysis to single cell sequencing and spatial transcriptomics.
Image credit: nobeastsofierce / stock.adobe.com
This Collection supports and amplifies research related to SDG 3: Good Health and Well-being.
The advent of high-throughput RNA sequencing technologies has revolutionized our understanding of complex diseases, particularly cancer, by unraveling the intricate landscape of gene expression dynamics. Bulk transcriptome analysis, single cell RNA sequencing (scRNA-seq), and spatial transcriptomics have emerged as indispensable tools in this endeavor, offering unprecedented resolution and depth in deciphering the molecular mechanisms underlying disease progression and therapeutic response.
Bulk transcriptome analysis enables the comprehensive profiling of gene expression patterns across populations of cells, providing valuable insights into dysregulated pathways and candidate biomarkers associated with disease phenotypes. Through differential expression analysis and pathway enrichment studies, bulk RNA sequencing has facilitated the identification of key molecular drivers and therapeutic targets in various cancer types, paving the way for precision medicine approaches.
Complementing bulk transcriptomics, scRNA-seq offers unparalleled resolution by capturing gene expression profiles at the single-cell level. This technology has unveiled the heterogeneity within tumor microenvironments, shedding light on rare cell populations, cellular states, and dynamic transcriptional trajectories that dictate disease progression and therapeutic resistance. Integration of scRNA-seq data with clinical outcomes has enabled the identification of novel prognostic markers and the development of personalized therapeutic strategies tailored to individual patients.
Furthermore, the recent advancements in spatial transcriptomics have provided spatial context to gene expression profiles, offering spatially resolved maps of the tumor microenvironment and its interactions with neighboring cells. This spatially resolved transcriptomic data has elucidated complex cellular interactions, immune infiltration patterns, and spatially restricted signaling networks within the tumor ecosystem, guiding the development of spatially targeted therapies and immunotherapies.
In this Collection, we highlight the transformative impact of RNA biology in unraveling the molecular underpinnings of complex diseases such as cancer, with a focus on the contributions of bulk transcriptome analysis, scRNA-seq, and spatial transcriptomics. We discuss recent technological advances, methodological considerations, and translational applications, underscoring the potential of RNA-centric approaches in driving precision medicine and improving clinical outcomes for patients with complex diseases.
Cell subsets differentially modulate host immune responses to Mycobacterium tuberculosis (MTB) infection. However, the nature and functions of these subsets against osteoarticular tuberculosis (OTB) are unclear. ...
This Collection welcomes submissions of original research and review articles. Should you wish to submit a different article type, please read our submission guidelines to confirm that type is accepted by the journal.
Articles for this Collection should be submitted via our submission system, Snapp. Please select the appropriate Collection title “Weaponizing RNA biology for combating complex diseases: From bulk transcriptome analysis to single cell sequencing and spatial transcriptomics" from the dropdown menu.
Articles will undergo the journal’s standard peer-review process and are subject to all the journal’s standard policies. Articles will be added to the Collection as they are published.
The Editors have no competing interests with the submissions which they handle through the peer-review process. The peer-review of any submissions for which the Editors have competing interests is handled by another Editorial Board Member who has no competing interests.